Last reviewed · How we verify
15-valent pneumococcal conjugate vaccine (PCV15) (15-valent-pneumococcal-conjugate-vaccine-pcv15)
This vaccine, PCV15, is marketed by Pfizer Inc. It is used to prevent invasive pneumococcal disease in adults 18 years and older, including those with certain underlying medical conditions or HIV infection. The vaccine targets 15 serotypes of Streptococcus pneumoniae. It is a conjugate vaccine, which means it combines a weakened form of the bacteria with a carrier protein to stimulate an immune response. PCV15 is a valuable tool in preventing pneumococcal disease, particularly in high-risk populations. Its clinical differentiation lies in its ability to protect against a wide range of serotypes. The commercial significance of PCV15 is its potential to reduce the burden of pneumococcal disease and related healthcare costs.
At a glance
| Generic name | 15-valent-pneumococcal-conjugate-vaccine-pcv15 |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | Streptococcus pneumoniae |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 50 years of age and older.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with certain underlying medical conditions.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with functional or anatomic asplenia.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with HIV infection.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with other conditions that compromise the immune system.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic kidney disease.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic liver disease.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic heart disease.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with chronic lung disease.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with diabetes.
- Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with alcohol use disorder.
Common side effects
Drug interactions
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
- Live, attenuated influenza vaccines
Key clinical trials
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (PHASE2)
- Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 (PHASE4)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) (PHASE3)
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age (PHASE1)
- Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: